China approves InnoCare Pharma’s BTK inhibitor for lymphoma
China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic lymphoma (SLL).
China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic lymphoma (SLL).
What's Your Reaction?
